1786O BMS-986012 (anti-fucosyl-monosialoganglioside-1 [fuc-GM1]) with carboplatin + etoposide + nivolumab (CE/NIVO) as first-line (1L) therapy in extensive-stage small cell lung cancer (ES-SCLC): Interim analysis (IA) of a randomized phase II study

E Kalinka,I Bahce,A.F Navarro Mendivil,N Ready,Q.S-C Chu,S Sugawara,A Sibille,M Provencio Pulla,M.L Johnson,J.T.J.N Hiltermann,T-E Ciuleanu,R Dziadziuszko,A Santo,Y Zhang,Y Liu,R Sarmiento,S Tannenbaum-Dvir,L Ojalvo,J Wu,K.J O'Byrne

doi:10.1016/j.annonc.2024.08.1877

1786O BMS-986012 (anti-fucosyl-monosialoganglioside-1 [fuc-GM1]) with carboplatin + etoposide + nivolumab (CE/NIVO) as first-line (1L) therapy in extensive-stage small cell lung cancer (ES-SCLC): Interim analysis (IA) of a randomized phase II study

E Kalinka, I Bahce + Show 18 more

https://doi.org/10.1016/j.annonc.2024.08.1877

Copy DOI

Journal: Annals of Oncology

Publication Date: Sep 1, 2024

#Extensive-stage Small Cell Lung Cancer #Interim Analysis + Show 7 more

Abstract
Full-Text
Similar Papers

Abstract

1786O BMS-986012 (anti-fucosyl-monosialoganglioside-1 [fuc-GM1]) with carboplatin + etoposide + nivolumab (CE/NIVO) as first-line (1L) therapy in extensive-stage small cell lung cancer (ES-SCLC): Interim analysis (IA) of a randomized phase II study

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Annals of Oncology

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.